Katie Ellias - Profile and Investment Details

Investor Profile

Katie Ellias is a Venture Capital, Private Equity Firm, Venture Debt, Investor based in Boston, Massachusetts, United States with a diverse investment portfolio that includes companies such as Tetragenetics, Biolinq, T1D Fund, SAb Biotherapeutics, Enthera, FACCNE ⎮ French-American Chamber of Commerce, New England, Endeavour Vision, Provention Bio, Protomer Technologies, Pandion Therapeutics, GluSense, DiogenX, Repertoire Immune Medicines, Seraxis, Semma TherapeuticsCapillary Biomedical, EGenesis, Medtronic, Enthera Pharmaceuticals, Sonoma BioTherapeutics, KE Advisory LLC, IMTherapeutics, ImmusanT, Immunocore, SQZ Biotech, Inversago Pharma, Diasome Pharmaceuticals, Pandion Therapeutics (acquired by Merck), Bigfoot Biomedical, Kriya Therapeutics, Veralox Therapeutics, Wharton Health Care Management Alumni Association, i2o Therapeutics, . Over time, Katie Ellias has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Katie Ellias is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Investment Management, AngularJS, Portfolio Management, Education, Finance, Biotechnology, Electronic Health Records (EHR), Health and Hospital Services, Productivity Software, Innovation, Consulting, Social Impact, Digital Health, Medical, B2B, Financial Advisory, Pharmaceuticals may find it worthwhile to explore potential connections with Katie Ellias, as their portfolio suggests a familiarity and interest in this area.

Understanding Katie Ellias’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.